Allan Oberman (CEO)
Sagent Pharmaceuticals is a biopharmaceutical company founded in 2007. The company received series A funding of $53 million, as well as $40 million in two rounds of series B funding. As part of the funding, Zhejiang Hisun Pharmaceutical Co. Ltd made an investment of $10 million in Sagent. In total, the company has raised $153 million in equity capital. In 2011 the company filed for IPO - offering 5,750,000 shares of common stock at a price to the public of $16 per share
The company was acquired by Nichi-Iko Pharmaceutical Co., Ltd in 2016.
In 2010, the company entered a partnership with Actavis to market and supply a number of injectable products.
In 2014, the company announced its intention to acquire Omega Laboratories Limited for $85.3 million
In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.
In 2016, the company made its most notable acquisition to date, when it acquired five Abbreviated New Drug Applications from Teva Pharmaceuticals for $40 million. As part of Teva's acquisition on Actavis Generics, a number of drug portfolios are being sold off. Later in the same year, the company was acquired by Nichi-Iko Pharmaceutical Co., Ltd for $736 million (representing $21.75 per share and a 40% share premium).